GLP-1 injections were originally developed and widely used as treatments for type 2 diabetes, helping people manage blood glucose through their effects on insulin, glucagon and insulin resistance reversal. Today, they are also widely recognised for their role in medical weight management.

This is because the same pathways involved in blood sugar regulation also influence appetite, fullness and food intake. By acting on these interconnected processes, GLP-1-based medications can support both sugar control and weight reduction, depending on the medication and its approved indication.

In this article, we explain what GLP-1 injections are, how they work for weight loss and blood sugar control, and what their effects can mean for longer-term metabolic health.

Understanding GLP-1 injections

GLP-1 stands for glucagon-like peptide-1, an ‘incretin’ hormone released from the gut after eating [1]. It helps the body respond to a meal by improving insulin and glucagon secretion, slowing gastric emptying and signaling fullness to the brain. These combined actions help regulate both appetite and blood glucose.

Natural GLP-1 (produced by our body), however, is short-lived. It is rapidly broken down by the enzyme dipeptidyl peptidase-4 (DPP-4), with active GLP-1 remaining in circulation for only a few minutes. GLP-1 receptor agonists are designed to overcome this limitation [2]. They activate the same receptors as natural GLP-1 but remain active for much longer, allowing the pathway to be used therapeutically.

Types of GLP-1-based injections

Not all medications commonly grouped under the term “GLP-1 injections” work in exactly the same way. An important distinction is whether a medication acts on the GLP-1 pathway alone or combines it with another incretin pathway.

• GLP-1 receptor agonists — Medications such as semaglutide and liraglutide activate GLP-1 receptors [3]. Their actions influence appetite and food intake while also affecting insulin and glucagon responses involved in blood glucose regulation.
• Dual GIP/GLP-1 receptor agonists — Tirzepatide activates receptors for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), another incretin hormone involved in metabolic regulation [4]. It is therefore more accurately described as a dual GIP/GLP-1 receptor agonist, even though it is often discussed alongside GLP-1 medications.

Both approaches use incretin pathways to influence metabolic function, but their mechanisms are not identical. This distinction becomes important when considering how different injections affect appetite, weight and blood sugar control.

How do GLP-1 injections work?

A common misconception is that GLP-1 injections directly burn or break down body fat. They do not. Instead, GLP-1 receptor agonists support weight loss primarily by influencing appetite and food intake, while also affecting digestion and the hormonal responses involved in blood sugar control. They do have a role in reversing insulin resistance which can then remove some of the effect of insulin reducing fat oxidation

After administration, a GLP-1 receptor agonist enters the circulation and activates GLP-1 receptors in several parts of the body. In the brain, GLP-1 signaling influences hunger and satiety. In the gastrointestinal tract, it can slow the rate at which food leaves the stomach. In the pancreas, it affects insulin and glucagon secretion in response to glucose.

Together, these effects can make it easier to consume less food while also helping the body regulate blood glucose.

Appetite and satiety signaling

Reduced hunger — GLP-1 receptors are found in areas of the brain involved in appetite regulation. Activating these pathways can reduce hunger and the drive to eat, which may make it easier to consume less food [5].

Increased satiety — GLP-1 signaling also enhances feelings of fullness and satisfaction after eating. People receiving GLP-1 treatment may feel satisfied with smaller portions and experience less desire to continue eating after a meal [6].

Over time, reduced hunger and increased satiety can lower overall energy intake. When this creates a sustained calorie deficit, body weight can decrease.

Gastric emptying and digestion

Slower gastric emptying — GLP-1 receptor activation can delay the movement of food from the stomach into the small intestine [7]. This can contribute to fullness after eating while also slowing the rate at which nutrients, including glucose, enter the intestine.

Longer-lasting fullness — Slower gastric emptying can help prolong the feeling of fullness after a meal. However, this works alongside GLP-1's effects on appetite signaling in the brain rather than being the sole reason people may eat less.

Insulin and glucagon response

GLP-1 receptor activation also influences two pancreatic hormones involved in blood glucose regulation: insulin and glucagon.

Insulin secretion — When blood glucose is elevated, GLP-1 receptor agonists stimulate pancreatic beta cells to release insulin [8]. This response is glucose-dependent, meaning the effect increases when blood glucose is higher rather than stimulating insulin release at the same level regardless of glucose concentration.

Glucagon suppression — GLP-1 receptor agonists also reduce glucagon secretion when glucose is elevated [9]. As glucagon signals the liver to produce and release glucose, reducing inappropriate glucagon secretion can help limit excess glucose entering the bloodstream.

Together with their effects on digestion, these hormonal responses can help lower fasting and post-meal blood glucose. GLP-1 receptor agonists are not insulin injections; instead, they influence the body's own response to changes in blood glucose. Overall the body becomes more efficient in it’s use of insulin to control sugar levels. 

GLP-1 Injections for weight loss

By reducing appetite and food intake, GLP-1 treatment can make it easier to maintain the calorie deficit needed for weight loss. Rather than producing an immediate change in body weight, weight loss typically occurs progressively over the course of treatment. 

How much weight a person loses varies. The medication prescribed, dose, duration of treatment, baseline weight, individual response and accompanying lifestyle changes can all influence the outcome. NIDDK notes that weight-loss outcomes with prescription medications vary considerably between individuals [11].

For people with overweight or obesity, the benefits of weight reduction can extend beyond the number on the scale. A 5–10% reduction in initial body weight can be associated with improvements in measures such as blood glucose, blood pressure and triglyceride levels, although the degree of benefit varies according to the individual and their underlying health.

GLP-1 Injections for blood sugar control

GLP-1 receptor agonists were used in the treatment of type 2 diabetes before their wider use in medical weight management. Through the glucose-dependent effects described above, they can help reduce both postprandial (after-meal) and fasting blood glucose.

This is particularly relevant in type 2 diabetes, where insulin resistance and progressive changes in pancreatic beta-cell function can make blood glucose increasingly difficult to regulate. Improving glycaemic control can help reduce persistently elevated glucose levels and forms an important part of managing the condition over time.

GLP-1 treatment is one of several approaches that may be used for type 2 diabetes. The appropriate treatment depends on factors such as a person's glycaemic status, other health conditions, treatment goals and existing medications.

Beyond weight Loss: the wider metabolic effects of GLP-1 treatment

The number on the scale does not tell the whole story. For people with overweight or obesity, losing weight can also be accompanied by changes in blood sugar, blood pressure, triglyceride levels and waist circumference. These improvements can be important when considering how treatment is affecting overall metabolic health.

It is also worth considering where the weight loss is coming from. When body weight decreases, a person can lose both body fat and lean mass, including muscle. This means that losing more kilograms does not necessarily mean achieving a better result.

Looking at factors such as waist circumference, blood sugar control and body composition alongside body weight can give a more complete picture of progress. This is also why maintaining muscle becomes an important part of healthy weight loss during GLP-1 treatment.

Preserving muscle during GLP-1-assisted weight loss

Loss of lean tissue is not unique to GLP-1 treatment; some lean mass is commonly lost whenever substantial weight loss occurs [12]. However, the degree of weight reduction achievable with GLP-1-based medications makes preserving muscle an important consideration. Body-composition studies of semaglutide and tirzepatide have generally shown that fat mass accounts for the greater proportion of weight lost, while lean mass also decreases [13].

• Adequate nutrition — A marked reduction in appetite can make it harder to consume sufficient protein and other essential nutrients. Nutritional intake, therefore, needs attention even when the primary treatment goal is weight loss. The most important factor is protein.
• Resistance exercise — Appropriate resistance training provides a stimulus for maintaining muscle during weight reduction. Combined with sufficient protein intake and regular physical activity, it can help support muscle mass and physical function as body weight falls.

Preserving lean tissue is crucial because muscle contributes to strength, mobility and metabolic function. The aim of treatment is therefore not simply to produce the largest possible fall in scale weight, but to achieve clinically meaningful weight reduction while supporting overall health and function.

What happens after GLP-1 injections are stopped?

Stopping GLP-1 treatment does not necessarily mean that the physiological factors influencing appetite and weight have resolved. As the medication leaves the body, the effects that helped support reduced food intake and weight loss can diminish.

• Appetite may increase — The appetite-regulating effects of GLP-1 treatment lessen after the medication is discontinued [14]. Hunger and food intake may increase again, particularly when the biological factors that contributed to weight gain remain present.
• Some weight regain can occur — Weight regain following treatment withdrawal has been documented in clinical trials. In the STEP 1 extension, participants regained approximately two-thirds of their previous semaglutide-associated weight loss within one year of stopping treatment [15]. This was an average study finding, however, and does not predict how much weight any individual will regain.

Key takeaway

GLP-1 injections can support both weight loss and blood sugar control, but they are not simply “fat-burning” injections. They work by changing signals involved in hunger, fullness, digestion and blood glucose regulation, which can make it easier to eat less while helping the body manage blood sugar more effectively.

Treatment also involves more than losing weight. Adequate nutrition, regular physical activity and maintaining muscle mass remain important, particularly as appetite and food intake decrease. How well treatment works, how long it is continued and whether it is appropriate will vary from person to person but is dependent on lifestyle change as well.

If you are considering GLP-1 injections for weight loss or blood sugar control, schedule a consultation with The Metabolic Clinic for an individual assessment and a medically supervised treatment plan.

Frequently Asked Questions (FAQs)

Persistent post-meal fatigue, frequent hunger and weight gain around the abdomen are often dismissed as stress or poor lifestyle habits. However, these subtle changes may be early signs of insulin resistance.

Insulin resistance develops gradually and rarely causes obvious symptoms in its early stages. Influenced by lifestyle habits, dietary patterns and genetics, it can quietly affect metabolism long before blood sugar levels become abnormal. Addressing insulin resistance early can help reduce the risk of type 2 diabetes, cardiovascular disease and fatty liver disease while supporting better long-term metabolic health.

In this blog, we explain what insulin resistance is, the early signs to look out for, who may be at greater risk and the steps that can help improve insulin sensitivity and protect your health.

Understanding insulin and insulin resistance

Insulin is a hormone produced by the pancreas that helps regulate blood sugar levels. After a meal, carbohydrates are broken down into glucose, which enters the bloodstream. Insulin allows glucose to move from the blood into the body's cells, where it is used for energy.

Insulin resistance occurs when the body's cells become less responsive to insulin [1]. As a result, glucose is less effectively absorbed by the cells, prompting the pancreas to produce more insulin to maintain normal blood sugar levels. Over time, this increased demand can place strain on the pancreas and contribute to rising blood sugar levels.

Why does this matter?

Although insulin resistance often develops silently, its effects can extend far beyond blood sugar levels. Over time, persistently elevated insulin and glucose levels can increase the risk of developing Type 2 Diabetes, Non-alcoholic Fatty Liver Disease and Cardiovascular Disease. Early identification and management of insulin resistance can help reduce the likelihood of these complications and support better long-term metabolic health.

What are the early signs of insulin resistance?

Early signs of insulin resistance often develop gradually and can be easy to miss in day-to-day life. They are frequently mistaken for routine fatigue, stress or minor dietary issues. Paying attention to these early changes can help identify underlying metabolic concerns and reduce the risk of more serious complications over time.

• Persistent fatigue after meals — Feeling unusually tired or sluggish after eating, especially after carbohydrate-heavy meals. This can happen without insulin resistance but is worse with insulin resistance. This may reflect the body’s reduced ability to use glucose efficiently despite higher insulin levels.
• Frequent sugar or carbohydrate cravings — A tendency to reach for sweets or refined foods throughout the day. Fluctuating blood sugar levels can trigger repeated hunger signals and cravings.
• Weight gain around the abdomen — Fat accumulation around the waist despite no major changes in diet or activity. This pattern is commonly linked to reduced insulin sensitivity.
• Feeling hungry soon after eating — Difficulty staying full even after a complete meal. Cells are not receiving enough glucose, leading the body to signal for more food.
• Brain fog or poor concentration — Difficulty focusing, mental fatigue or reduced clarity during the day. Irregular glucose uptake by the brain can affect cognitive function.
• Darkened skin patches (acanthosis nigricans) — Areas of darker, thicker skin, often around the neck, underarms or groin. This is a visible sign associated with higher insulin levels.
• Borderline blood test results — Slightly elevated fasting glucose, HbA1c or triglycerides without a formal diagnosis. These early changes may indicate underlying insulin resistance.

Who is more likely to experience insulin resistance?

Although insulin resistance can affect anyone, it is more commonly seen in people with certain metabolic conditions, body-composition patterns or inherited risk factors.

• People living with obesity or are overweight — Excess body fat, particularly visceral fat stored around the abdominal organs, can release inflammatory substances and fatty acids that interfere with insulin signaling. However, insulin resistance can also occur in people who are not overweight.
• People with prediabetes or type 2 diabetes — Insulin resistance commonly develops before blood sugar levels become abnormal. In prediabetes, the pancreas may still produce enough additional insulin to compensate. Type 2 diabetes can develop when this compensation is no longer sufficient to maintain healthy blood sugar levels.
• Women with PCOS — Insulin resistance is common among women with polycystic ovary syndrome and may contribute to elevated androgen levels, irregular periods, difficulties with weight management and fertility concerns.
• People with a history of gestational diabetes — Developing diabetes during pregnancy is associated with a higher likelihood of insulin resistance and type 2 diabetes later in life.
• People with metabolic syndrome or fatty liver disease — A large waist circumference, high triglycerides, low HDL cholesterol, elevated blood pressure and metabolic dysfunction-associated steatotic liver disease (MASLD) frequently occur alongside insulin resistance.
• People with a family history or higher inherited risk — Having a close relative with type 2 diabetes can increase the likelihood of insulin resistance. People of Asian ethnicity may also develop metabolic risk at a lower BMI than some other populations.

Ageing, physical inactivity, poor sleep, smoking and certain hormonal or medical conditions can further increase the likelihood of developing insulin resistance. Importantly, appearance or body weight alone cannot confirm or exclude the condition.

When should you see a doctor for insulin resistance?

It is advisable to seek medical evaluation if early symptoms persist or begin to affect daily functioning. Ongoing fatigue, frequent hunger or difficulty maintaining energy levels despite regular meals may indicate underlying metabolic imbalance. Individuals with a strong family history of Type 2 Diabetes should be particularly mindful, as genetic predisposition can increase the likelihood of developing insulin resistance at an earlier stage.

Medical attention is also important if routine screening tests show borderline or abnormal results, even in the absence of clear symptoms. Difficulty losing weight despite consistent dietary control and physical activity may further suggest reduced insulin sensitivity. Early assessment allows for timely intervention, helping to prevent progression to more serious metabolic conditions and enabling a more targeted approach to management.

How can an Endocrinologist help?

An endocrinologist can assess your overall metabolic health, identify factors contributing to insulin resistance and determine whether related conditions such as prediabetes, Type 2 Diabetes, PCOS or fatty liver disease are present. This typically involves a review of symptoms, medical history, lifestyle habits and blood test results.

Based on the findings, a personalised management plan can be developed to improve insulin sensitivity and reduce long-term health risks. This may include dietary guidance, exercise recommendations, weight management strategies, metabolic monitoring and medical treatment where appropriate.

How is insulin resistance treated?

For most individuals, treatment begins with lifestyle modifications, while medication may be recommended for selected patients depending on their overall metabolic health and treatment goals.

Lifestyle modifications

Lifestyle changes form the foundation of insulin resistance treatment. A balanced diet rich in whole foods, lean protein, healthy fats and fibre can help support more stable blood sugar levels while reducing excessive insulin demand. Regular physical activity, including both aerobic exercise and resistance training, helps the muscles use glucose more efficiently and improves insulin sensitivity.

Weight management may also play an important role. For individuals who are overweight or obese, even modest weight loss can lead to meaningful improvements in insulin sensitivity and overall metabolic health. Adequate sleep, effective stress management and smoking cessation further support healthy glucose regulation and may reduce the progression of insulin resistance.

How can GLP-1 medicines help with insulin resistance?

GLP-1 receptor agonists mimic the action of glucagon-like peptide-1, a hormone naturally released by the gut after eating. When blood glucose is elevated, these medications help the pancreas release insulin while reducing glucagon, a hormone that prompts the liver to release glucose. They may also slow gastric emptying, reduce appetite and help patients feel satisfied with less food.

For people living with obesity or are overweight, the resulting reduction in calorie intake and body weight, particularly excess visceral and liver fat, can help the muscles and liver respond more effectively to insulin. This improves insulin sensitivity and reduces the amount of insulin needed to regulate blood sugar.

Dual GIP/GLP-1 receptor agonists act on both GIP and GLP-1 pathways. They similarly support glucose-dependent insulin release, reduce glucagon levels and promote weight loss. Tirzepatide, for example, has also demonstrated increased insulin sensitivity in clinical studies.

These medications are generally prescribed for approved indications such as type 2 diabetes or chronic weight management where it has caused metabolic disease such as hypertension/ dyslipidaemia/ Metabolic dysfunction associated with steatotic liver disease, rather than insulin resistance alone. An endocrinologist can assess whether they are appropriate based on the individual’s overall health, treatment goals and potential risks.

Ongoing monitoring

Regular follow-up allows treatment to be adjusted as metabolic health changes over time. Blood tests, weight, blood pressure and other metabolic markers may be monitored periodically to assess progress and identify any changes that require further intervention. Ongoing monitoring also provides an opportunity to reinforce healthy lifestyle habits and optimise long-term metabolic health.

Summary 

Although receiving a diagnosis of insulin resistance may feel concerning, identifying it early is actually an opportunity to take action before it progresses to more serious metabolic conditions. In many individuals, insulin resistance can be significantly improved and, in some cases, return to normal when it is recognised early and managed with appropriate lifestyle changes and medical treatment where needed.

If you are experiencing symptoms of insulin resistance or have concerns about your metabolic health, schedule a consultation with The Metabolic Clinic. Early assessment allows for personalised treatment that can help improve insulin sensitivity, reduce the risk of developing prediabetes or type 2 diabetes, and support better long-term health.

Frequently Asked Questions (FAQ) 

References 

1. CDC. (2024, May 31). About insulin resistance and type 2 diabetes. Diabetes. https://www.cdc.gov/diabetes/about/insulin-resistance-type-2-diabetes.html 
2. Nogueira, J. P., & Cusi, K. (2024). Role of insulin resistance in the development of nonalcoholic fatty liver disease in people with type 2 diabetes: From bench to patient care. Diabetes Spectrum: A Publication of the American Diabetes Association, 37(1), 20–28. https://doi.org/10.2337/dsi23-0013 
3. Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023). Insulin resistance and cardiovascular disease. The Journal of International Medical Research, 51(3), 03000605231164548. https://doi.org/10.1177/03000605231164548 
4. Shah, A., & Kanaya, A. M. (2014). Diabetes and associated complications in the south asian population. Current Cardiology Reports, 16(5), 476. https://doi.org/10.1007/s11886-014-0476-5 
5. Is insulin resistance the same as diabetes? (2023, September 5). Healthline. https://www.healthline.com/health/is-insulin-resistance-the-same-as-diabetes  
6. Insulin resistance & prediabetes—Niddk. (n.d.). National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved May 5, 2026, from https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance 
7. Taylor, R. (2012). Insulin resistance and type 2 diabetes. Diabetes, 61(4), 778–779. https://doi.org/10.2337/db12-0073 
8. Horáková, D., Štěpánek, L., Janout, V., Janoutová, J., Pastucha, D., Kollárová, H., Petráková, A., Štěpánek, L., Husár, R., & Martiník, K. (2019). Optimal homeostasis model assessment of insulin resistance (Homa-ir) cut-offs: A cross-sectional study in the czech population. Medicina, 55(5), 158. https://doi.org/10.3390/medicina55050158 
9. H. Ibrahim, S. M., Shahat, E. A., Amer, L. A., & Aljohani, A. K. (n.d.). The impact of using carbohydrate counting on managing diabetic patients: A review. Cureus, 15(11), e48998. https://doi.org/10.7759/cureus.48998 
10. Murillo, S., Mallol, A., Adot, A., Juárez, F., Coll, A., Gastaldo, I., & Roura, E. (2022). Culinary strategies to manage glycemic response in people with type 2 diabetes: A narrative review. Frontiers in Nutrition, 9, 1025993. https://doi.org/10.3389/fnut.2022.1025993 
11. Mphasha, M. H., & Vagiri, R. (2025). A narrative review of the interplay between carbohydrate intake and diabetes medications: Unexplored connections and clinical implications. International Journal of Molecular Sciences, 26(2), 624. https://doi.org/10.3390/ijms26020624 
12. DiNicolantonio, J. J., & O’Keefe, J. H. (2022). Added sugars drive insulin resistance, hyperinsulinemia, hypertension, type 2 diabetes and coronary heart disease. Missouri Medicine, 119(6), 519–523. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762218/ 
13. Alahmari, L. A. (2024). Dietary fiber influence on overall health, with an emphasis on CVD, diabetes, obesity, colon cancer, and inflammation. Frontiers in Nutrition, 11, 1510564. https://doi.org/10.3389/fnut.2024.1510564 

Condition	Diabetic neuropathy
Common symptoms	Tingling, numbness, burning pain, reduced sensation
Most commonly affects	Feet and legs
Cause	Long-term diabetes-related nerve damage
Can it be reversed?	Established nerve damage cannot always be reversed, but progression can often be slowed
Treatment	Blood glucose optimisation, lifestyle measures, medications for nerve pain, foot care

Persistent tingling, burning, numbness or unusual sensations, particularly in someone living with diabetes, may be an early sign of diabetic neuropathy. This common complication of diabetes develops when persistently elevated blood glucose damages the nerves over time, increasing the risk of loss of sensation, unnoticed injuries, foot ulcers, infections and, in severe cases, amputation if left untreated.

Because diabetic neuropathy often develops gradually, its early symptoms may be mistaken for normal ageing, poor circulation or temporary nerve irritation. Early diagnosis and appropriate diabetes management are important to help slow disease progression, relieve symptoms and reduce the risk of serious complications.

In this article, we explain what diabetic neuropathy is, its symptoms, causes and risk factors, how it is diagnosed, and the treatment and lifestyle measures that can help protect nerve health.

What is diabetic neuropathy?

Diabetic neuropathy is a type of nerve damage caused by diabetes. Persistently elevated blood glucose levels, together with other metabolic changes associated with diabetes, can gradually damage the nerves and the small blood vessels that supply them with oxygen and nutrients [1]. Although diabetic neuropathy can affect nerves throughout the body, the most common form, peripheral diabetic neuropathy, primarily affects the feet and legs before potentially progressing to the hands.

Unlike the temporary “pins and needles” that occur after sitting in one position for too long, diabetic neuropathy results from ongoing nerve damage. Without appropriate diabetes management, the condition can progress over time, leading to persistent pain, numbness, loss of sensation and an increased risk of foot injuries and other complications.

Why are feet usually affected first?

Diabetic neuropathy usually affects the feet first because the nerves supplying the feet are the longest in the body. Longer nerves are generally more vulnerable to damage caused by persistently elevated blood glucose and other metabolic changes associated with diabetes. As a result, symptoms often begin in the toes before gradually spreading upwards through the feet and lower legs. As nerve damage progresses, the hands may also become affected, resulting in the characteristic "stocking-and-glove" pattern of diabetic peripheral neuropathy.

Signs and symptoms of diabetic neuropathy

The symptoms of diabetic neuropathy vary from person to person and often develop gradually over months or years. In the early stages, some people may notice only occasional tingling or mild numbness, while others experience burning discomfort or increased sensitivity. As nerve damage progresses, symptoms may become more frequent and begin to interfere with daily activities, sleep and mobility.

Common symptoms of diabetic peripheral neuropathy include:

• Tingling or “pins and needles” sensations, particularly in the feet or toes
• Numbness or reduced ability to feel pain, temperature or touch
• Burning, sharp, stabbing or shooting pain that may worsen at night
• Increased sensitivity to touch, where even bedsheets or socks may feel uncomfortable
• Muscle weakness or reduced coordination
• Difficulty with balance or walking due to loss of sensation in the feet

Because sensation is reduced, many people may not notice cuts, blisters or burns on their feet until they become infected. This is why recognising the symptoms of diabetic neuropathy early and seeking timely medical evaluation is essential to prevent more serious complications. Those with diabetes neuropathy must do daily self-checks of their feet to pick up trauma early and prevent progression to a diabetes foot infection.

Types of diabetic neuropathy

Diabetic neuropathy can affect different nerves throughout the body, depending on which nerves have been damaged. The four main types include:

Type	Commonly affects	Symptoms
Peripheral	Feet, legs, hands	Tingling, numbness, burning pain
Autonomic	Internal organs	Digestive, bladder, heart rate or sweating problems
Proximal	Hip, thigh, buttocks	Pain and muscle weakness
Focal	Single nerve	Sudden weakness or pain in one area

Peripheral diabetic neuropathy is by far the most common type and is responsible for the tingling, numbness and burning sensations experienced by many people with diabetes.

Could tingling or numbness be caused by something else?

Although diabetic neuropathy is one of the most common causes of tingling and numbness in people with diabetes, these symptoms are not always caused by nerve damage related to diabetes. Several other medical conditions can produce similar symptoms and may require different treatment.

Possible causes include:

• Vitamin B12 deficiency, particularly in people taking metformin long term
• Carpal tunnel syndrome or other nerve compression disorders
• A trapped nerve in the neck or lower back
• Thyroid disorders
• Kidney disease
• Peripheral arterial disease (poor circulation)
• Alcohol-related nerve damage
• Certain medications that affect the nerves

Because the causes of tingling and numbness can overlap, a medical assessment is important to identify the underlying condition and determine the most appropriate treatment. Your doctor may recommend blood tests or other investigations to rule out alternative causes before confirming a diagnosis of diabetic neuropathy.

When should tingling or numbness be checked by a doctor?

Persistent tingling, numbness or burning sensations should never be ignored, especially if you have diabetes. Early medical evaluation can help identify whether your symptoms are due to diabetic neuropathy or another underlying condition and allows appropriate treatment to begin before complications develop.

You should arrange a medical assessment if your symptoms:

• Persist or keep recurring
• Affect both feet or both hands
• Gradually spread or become more severe
• Disturb your sleep
• Cause weakness, poor balance or difficulty walking
• Reduce your ability to feel pain, temperature or touch
• Occur together with a foot wound, blister, swelling or skin colour changes
• Occur in the hands early on (suggesting a process other than diabetes)

Seek prompt medical attention if you experience:

• A foot wound that is not healing
• Redness, warmth, swelling, discharge or an unpleasant odour from a foot wound
• Fever together with a foot wound
• A sudden loss of sensation or muscle strength
• Rapidly worsening symptoms
• Severe numbness or weakness affecting one side of the body

Sudden numbness or weakness should not be assumed to be diabetic neuropathy, as it may indicate another serious medical condition requiring urgent assessment, such as a stroke. Prompt medical attention is essential in these situations.

How is diabetic neuropathy diagnosed?

There is no single test that confirms diabetic neuropathy. Instead, the diagnosis is based on a combination of your symptoms, medical history and physical examination. Your doctor will assess the pattern and progression of your symptoms while looking for signs of nerve damage and excluding other possible causes of tingling or numbness.

During the assessment, your doctor may evaluate:

• The location, pattern and duration of your symptoms
• Your diabetes history and blood glucose control
• Current medications and other medical conditions
• Sensation in your feet and legs
• Reflexes and muscle strength
• Balance and walking
• The condition of your skin, foot pulses and any foot deformities

Depending on your symptoms, your doctor may recommend one or more of the following tests:

• Monofilament testing to assess protective sensation in the feet [13]
• Vibration testing using a tuning fork [14]
• Pinprick or temperature sensation testing
• Blood tests to identify other possible causes, such as vitamin B12 deficiency or thyroid disorders
• Nerve conduction studies or electromyography (EMG) in selected cases when the diagnosis is uncertain or another nerve disorder is suspected

Not everyone requires specialised nerve tests. In many cases, a typical history and physical examination provide sufficient information to diagnose diabetic peripheral neuropathy and guide treatment.

How is Diabetic Neuropathy Treated?

Treatment focuses on slowing the progression of nerve damage, relieving symptoms and reducing the risk of complications such as foot ulcers and infections. The most appropriate treatment plan varies from person to person and is tailored to the severity of symptoms, overall health and diabetes control.

Maintaining good diabetes control is one of the most important ways to slow the progression of diabetic neuropathy. Instead of aiming for rapid or extreme reductions in blood glucose, treatment focuses on achieving personalised targets safely and consistently under medical supervision.

A comprehensive management plan may include:

• Optimising blood glucose levels
• Managing blood pressure
• Controlling cholesterol and triglyceride levels
• Quitting smoking
• Engaging in regular physical activity
• Following a balanced, nutritious diet and sometimes supplementation with additional antioxidants
• Achieving and maintaining a healthy weight, where appropriate

For people experiencing neuropathic pain, doctors may also recommend medications specifically designed to relieve nerve pain, alongside regular foot care and monitoring to reduce the risk of complications.

Neuropathic pain differs from pain caused by muscle or joint injuries and often does not respond well to conventional painkillers. Instead, doctors may prescribe medications that target abnormal nerve signalling to help relieve burning, tingling or shooting pain. The most appropriate treatment depends on your symptoms, overall health and individual treatment goals.

Can diabetic neuropathy be prevented?

Diabetic neuropathy cannot always be prevented, but maintaining good diabetes control and addressing other risk factors can significantly reduce the likelihood of developing nerve damage or slow its progression. Regular monitoring is especially important because neuropathy may develop gradually before symptoms become noticeable.

Measures that may help reduce the risk include:

• Attending regular diabetes reviews
• Maintaining personalised blood glucose targets
• Controlling blood pressure and cholesterol levels
• Stopping smoking
• Staying physically active
• Following a balanced, healthy diet
• Practising proper daily foot care
• Undergoing annual foot and neuropathy screening

Seeking medical advice promptly if new symptoms such as tingling, numbness or burning sensations develop

Early detection and proactive diabetes management remain the most effective strategies for protecting nerve health and preventing long-term complications.

Schedule a consultation

Tingling, numbness or burning sensations should never be dismissed as a normal part of ageing or simply “poor circulation,” especially if you have diabetes. While these symptoms are commonly associated with diabetic neuropathy, they can also result from other underlying conditions that require medical evaluation. 

Managing diabetic neuropathy goes beyond relieving nerve pain. It requires a comprehensive approach that includes optimising blood glucose control, addressing cardiovascular risk factors, practising good foot care and attending regular diabetes reviews. With appropriate treatment and ongoing monitoring, many people can successfully manage their symptoms and protect their long-term nerve health.

If you are experiencing persistent tingling, numbness, burning sensations or nerve pain, consider scheduling a consultation with The Metabolic Clinic for a comprehensive assessment, personalised diabetes management and early screening for diabetic neuropathy.

Frequently Asked Questions (FAQs)

References

1. Yang, Y., Zhao, B., Wang, Y., Lan, H., Liu, X., Hu, Y., & Cao, P. (2025). Diabetic neuropathy: Cutting-edge research and future directions. Signal Transduction and Targeted Therapy, 10, 132. https://doi.org/10.1038/s41392-025-02175-1 
2.  Bodman, M. A., Dreyer, M. A., & Varacallo, M. A. (2026). Diabetic peripheral neuropathy. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK442009/ 
3. Pop-Busui, R., Ang, L., Boulton, A. J. M., Feldman, E. L., Marcus, R. L., Mizokami-Stout, K., Singleton, J. R., & Ziegler, D. (2022). Diagnosis and treatment of painful diabetic peripheral neuropathy. American Diabetes Association. http://www.ncbi.nlm.nih.gov/books/NBK580224/ 
4. What is diabetic neuropathy? - Niddk. (n.d.). National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved July 16, 2026, from https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/nerve-damage-diabetic-neuropathies/what-is-diabetic-neuropathy 
5. Lee, J.-E., & Won, J. C. (2025). Clinical phenotypes of diabetic peripheral neuropathy: Implications for phenotypic-based therapeutics strategies. Diabetes & Metabolism Journal, 49(4), 542–564. https://doi.org/10.4093/dmj.2025.0299 
6. Autonomic neuropathy—Niddk. National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved July 16, 2026, from https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/nerve-damage-diabetic-neuropathies/autonomic-neuropathy  
7. Proximal neuropathy—Niddk. National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved July 16, 2026, from https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/nerve-damage-diabetic-neuropathies/proximal-neuropathy 
8. Focal neuropathies—Niddk. National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved July 16, 2026, from https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/nerve-damage-diabetic-neuropathies/focal-neuropathies 
9. Armstrong, D. G., Bley, K., Simpson, D. M., Staats, P., Allen, S., Carnevale, A., & Marcondes, L. (2025). Diabetic peripheral neuropathy: Pathophysiology and new insights into the mechanism of action of high-concentration topical capsaicin. Journal of Experimental Pharmacology, 17, 651–665. https://doi.org/10.2147/JEP.S526968 
10. Never Damage. Diabetes. Centre for Disease Control and Prevention. https://www.cdc.gov/diabetes/diabetes-complications/diabetes-and-nerve-damage.html 
11. Sevy, J. O., Sina, R. E., & Varacallo, M. A. (2026). Carpal tunnel syndrome. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK448179/ 
12. Al Zoubi, M. S., Al Kreasha, R., Aqel, S., Saeed, A., Al-Qudimat, A. R., & Al-Zoubi, R. M. (2024). Vitamin B12 deficiency in diabetic patients treated with metformin: A narrative review. Irish Journal of Medical Science, 193(4), 1827–1835. https://doi.org/10.1007/s11845-024-03634-4 
13. Dros, J., Wewerinke, A., Bindels, P. J., & van Weert, H. C. (2009). Accuracy of monofilament testing to diagnose peripheral neuropathy: A systematic review. Annals of Family Medicine, 7(6), 555–558. https://doi.org/10.1370/afm.1016 
14. Yang, Z., Zhang, Y., Chen, R., Huang, Y., Ji, L., Sun, F., Hong, T., & Zhan, S. (2018). Simple tests to screen for diabetic peripheral neuropathy. The Cochrane Database of Systematic Reviews, 2018(7), CD010975. https://doi.org/10.1002/14651858.CD010975.pub2 

What if heart disease, kidney disease and diabetes weren’t separate diseases at all?

For decades, these conditions have been treated independently. But research now shows they are closely interconnected. Problems that begin with excess body fat or insulin resistance can gradually affect the kidneys, while declining kidney function can place additional strain on the heart. Rather than existing in isolation, each condition can fuel the progression of the others.

This concept is known as Cardiorenal Metabolic Syndrome (CKM Syndrome), a framework that recognises the heart, kidneys and metabolic system as part of one interconnected network. Understanding this relationship allows doctors to identify risk earlier, intervene sooner and reduce the likelihood of serious complications such as heart attack, stroke, heart failure and chronic kidney disease.

In this article, we'll explain what Cardiorenal Metabolic Syndrome is, why it matters and how protecting one organ often means protecting them all.

Cardiorenal Metabolic Syndrome at a Glance

What is it?	A framework that recognises the close relationship between the heart, kidneys and metabolic system, where dysfunction in one can affect the others.
Common risk factors	Obesity, insulin resistance, prediabetes, type 2 diabetes, high blood pressure, abnormal cholesterol and chronic kidney disease.
Potential complications	Heart attack, stroke, heart failure, chronic kidney disease and other cardiovascular complications.
Early warning signs	Increasing waist circumference, elevated blood pressure, rising blood sugar, abnormal cholesterol, protein in the urine and declining kidney function.
Can it be prevented?	In many cases, yes. Early identification of risk factors, healthy lifestyle changes and appropriate medical treatment can slow or prevent disease progression.
Who should be assessed?	Individuals with obesity, diabetes, hypertension, chronic kidney disease or multiple cardiometabolic risk factors.

What is cardiorenal metabolic syndrome?

Cardiorenal Metabolic Syndrome (CKM Syndrome) [1], also known as Cardiovascular-Kidney-Metabolic Syndrome, is a term used to describe the close relationship between cardiovascular disease, kidney disease and metabolic disorders such as obesity, insulin resistance and type 2 diabetes. It reflects the understanding that these conditions are not isolated health problems but are interconnected through shared risk factors and biological processes.

Traditionally, heart disease, kidney disease and metabolic disorders have been managed as separate conditions. However, growing evidence has shown that dysfunction in one area often affects the others [2]. For example, obesity and insulin resistance can increase the risk of high blood pressure and type 2 diabetes, both of which can damage the heart and kidneys over time [3]. Similarly, kidney disease can increase cardiovascular risk [4], while heart disease can contribute to declining kidney function [5]. These interactions have prompted a more integrated approach to understanding and managing chronic disease.

Cardiorenal Metabolic Syndrome places emphasis on identifying and addressing risk factors early, before significant organ damage occurs. By recognising the links between metabolic, cardiovascular and kidney health, healthcare professionals can take a more comprehensive approach to prevention, risk assessment and treatment.

How are the heart, kidneys and metabolic system connected?

Cardiorenal Metabolic Syndrome develops because the heart, kidneys and metabolic system constantly influence one another. Changes affecting one system can trigger a chain reaction that impacts the others, creating a cycle of progressive disease.

Connection	What happens?	Why it matters
Metabolic System → Heart	Excess body fat, insulin resistance and elevated blood sugar promote chronic inflammation, endothelial dysfunction and damage to blood vessels.	Increases the risk of high blood pressure, atherosclerosis, coronary artery disease and heart failure.
Metabolic System → Kidneys	Elevated blood sugar damages the small blood vessels in the kidneys, while obesity, insulin resistance and hypertension place additional strain on kidney function.	Increases the risk of chronic kidney disease (CKD) and reduces the kidneys' ability to filter waste effectively.
Kidneys → Heart	Declining kidney function causes fluid retention, hormonal imbalances and elevated blood pressure.	Places extra strain on the heart, increasing the risk of heart failure and other cardiovascular complications.
Heart → Kidneys	Heart disease can reduce blood flow to the kidneys, limiting the oxygen and nutrients they receive.	Can accelerate kidney damage and contribute to worsening kidney function.
The Cardiorenal Connection	Heart disease and kidney disease have a bidirectional relationship, meaning dysfunction in one organ can worsen the other.	Creates a cycle where cardiovascular and kidney disease progressively reinforce one another, increasing the risk of serious complications.

Early warning signs to look out for

One of the challenges of Cardiorenal Metabolic Syndrome is that it often develops gradually and may not cause obvious symptoms in its early stages. In many cases, the first signs are detected through routine health screenings rather than physical symptoms.

Potential early warning signs include:

• Increasing waist circumference or central weight gain
• Elevated blood pressure readings
• Rising fasting blood glucose or HbA1c levels
• Abnormal cholesterol or triglyceride levels
• Fatty liver detected on imaging
• Protein or albumin detected in the urine
• Declining kidney function on blood tests
• Reduced exercise tolerance
• Persistent fatigue or low energy levels

As the condition progresses, some individuals may develop symptoms related to cardiovascular or kidney disease, including swelling in the ankles, shortness of breath, chest discomfort or changes in urinary habits. However, many people remain symptom-free until significant disease has already developed, highlighting the importance of regular health screening.

The stages of cardiorenal metabolic syndrome

Cardiorenal Metabolic Syndrome develops along a continuum rather than appearing suddenly. To help identify risk earlier and guide preventive care, the American Heart Association (AHA) has proposed a staging system that reflects the progression from optimal health to established cardiovascular disease [21].

Stage 0: Optimal Health	Stage 0 refers to individuals with healthy cardiovascular, kidney and metabolic function. There are no significant risk factors, and measures such as body weight, blood pressure, blood sugar and kidney function remain within healthy ranges.
Stage 1: Excess or Dysfunctional Body Fat	At this stage, excess body fat, particularly abdominal or visceral fat, begins to affect metabolic health. Although significant disease may not yet be present, changes in body composition can increase the risk of future insulin resistance, hypertension and cardiovascular disease.
Stage 2: Metabolic Risk Factors or Early Kidney Disease	Stage 2 is characterised by the presence of one or more metabolic risk factors, such as elevated blood pressure, abnormal cholesterol levels, prediabetes, type 2 diabetes or evidence of early kidney dysfunction. This stage often represents an important opportunity for intervention before significant organ damage occurs.
Stage 3: Increased Cardiovascular Risk	Individuals in Stage 3 have developed a higher likelihood of cardiovascular disease due to the cumulative effects of metabolic and kidney-related risk factors. Structural or functional changes affecting the heart and blood vessels may already be present, even if symptoms have not yet developed.
Stage 4: Established Cardiovascular Disease	Stage 4 involves clinically recognised cardiovascular disease, such as coronary artery disease, heart attack, stroke, heart failure or peripheral arterial disease. At this stage, comprehensive management is essential to reduce complications and improve long-term outcomes.

Importantly, progression through these stages is not inevitable. Early identification of risk factors and appropriate intervention can slow disease progression and, in some cases, prevent advancement to more severe stages.

How is cardiorenal metabolic syndrome diagnosed?

There is no single test that confirms Cardiorenal Metabolic Syndrome. Diagnosis involves evaluating multiple aspects of cardiovascular, kidney and metabolic health to identify risk factors and determine the extent of disease.

• Medical History and Risk Assessment  — A healthcare professional will review personal and family medical history, current health conditions, lifestyle factors and any symptoms that may suggest cardiovascular, metabolic or kidney-related disease.
• Blood Pressure Measurement  — Blood pressure is a key component of cardiometabolic health. Persistently elevated readings can indicate increased cardiovascular and kidney disease risk.
• Blood Tests  — Several blood tests may be performed to assess metabolic and kidney function, including:
  • HbA1c to evaluate long-term blood sugar control
  • Fasting blood glucose to identify prediabetes or diabetes 
  • Fasting insulin levels to identify insulin resistance prior to prediabetes
  • Lipid profile to assess cholesterol and triglyceride levels
  • Kidney function tests such as serum creatinine and estimated glomerular filtration rate (eGFR)
• Urine Testing  — Urine tests can detect the presence of protein or albumin, which may indicate early kidney damage before symptoms become apparent.
• Body Composition Assessment  — Measurements such as body mass index (BMI), waist circumference and body fat distribution help assess obesity-related risk and metabolic health. At the metabolic clinic we prefer DEXA body composition scans.
• Cardiovascular Risk Evaluation  — Additional investigations may be recommended depending on an individual’s risk profile. These may include cardiovascular imaging, electrocardiography (ECG) or other assessments used to evaluate heart and vascular health.

How is cardiorenal metabolic syndrome treated?

Treatment aims to reduce overall disease risk by addressing cardiovascular, kidney and metabolic health simultaneously. Management plans are tailored to the individual's health profile and risk factors.

• Lifestyle and Nutrition Changes  — Lifestyle modification forms the foundation of treatment. A balanced dietary pattern that supports healthy weight management, blood sugar control and cardiovascular health is often recommended.
• Weight Management  — For individuals who are overweight or obese, achieving and maintaining a healthy weight can improve metabolic function, lower blood pressure and reduce strain on the cardiovascular and renal systems.
• Physical Activity — Regular exercise supports cardiovascular fitness, improves insulin sensitivity and contributes to better overall metabolic health. Physical activity recommendations should be tailored to individual abilities and medical conditions.
• Blood Sugar Management — Effective control of blood glucose levels helps reduce the risk of diabetes-related complications and protects both cardiovascular and kidney health.
• Blood Pressure Control — Maintaining healthy blood pressure levels is important for reducing strain on the heart and minimising kidney damage.
• Cholesterol Management — Improving cholesterol and triglyceride levels can help lower the risk of atherosclerosis and cardiovascular disease.
• Medications — Depending on an individual's risk profile and existing medical conditions, medications may be prescribed to manage blood pressure, blood sugar, cholesterol levels or kidney disease. Newer therapies may provide benefits across multiple aspects of cardiometabolic health and the use of these medications such as GLP-1 Agonists and SGLT-2 inhibitors have revolutionised cardiorenal metabolic syndrome by addressing route causes.

When should you visit an Endocrinologist?

Consider seeing an endocrinologist if you have one or more risk factors for Cardiorenal Metabolic Syndrome, particularly if lifestyle changes alone have not been enough to improve your health. Early assessment can help identify metabolic abnormalities before they progress to cardiovascular or kidney disease.

You should consider scheduling an appointment if you:

• Have overweight or obesity, particularly excess abdominal fat.
• Have prediabetes or type 2 diabetes.
• Have persistently elevated blood pressure or abnormal cholesterol levels.
• Have insulin resistance or metabolic syndrome.
• Have abnormal kidney function or protein detected in your urine.
• Have fatty liver disease alongside metabolic risk factors.
• Have a family history of type 2 diabetes, cardiovascular disease or chronic kidney disease.
• Are struggling to lose weight despite consistent diet and exercise.
• Have been diagnosed with one cardiometabolic condition and would like a comprehensive assessment of your overall cardiovascular, kidney and metabolic health.

Early intervention may help slow disease progression, reduce the risk of long-term complications and support better heart, kidney and metabolic health.

Summary

Cardiorenal Metabolic Syndrome recognises that the heart, kidneys and metabolic system are closely interconnected. Risk factors such as obesity, insulin resistance, high blood pressure and abnormal cholesterol can affect multiple organ systems simultaneously, increasing the likelihood of heart disease, chronic kidney disease and other long-term complications. Early identification and management can help slow disease progression and improve long-term health outcomes.

If you have concerns about your weight, blood sugar, blood pressure, cholesterol or kidney health, or have multiple cardiometabolic risk factors, consider booking a consultation with the team at The Metabolic Clinic. A personalised assessment can help identify your risk factors and develop a tailored management plan to support your long-term cardiovascular, kidney and metabolic health.

References 

1. Singh, A., Kesani, H., Verma, S., Saleh, T. M., & Rai, M. (n.d.). Cardio-renal metabolic syndrome: An integrated approach to prevention and management. Cureus, 17(10), e94134. https://doi.org/10.7759/cureus.94134 
2. Tanasescu, M.-D., Rosu, A.-M., Minca, A., Rosu, A.-L., Grigorie, M.-M., Timofte, D., & Ionescu, D. (2026). Metabolic dysfunction at the core: Revisiting the overlap of cardiovascular, renal, hepatic, and endocrine disorders. Life, 16(1), 172. https://doi.org/10.3390/life16010172 
3. Wondmkun, Y. T. (2020). Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 13, 3611–3616. https://doi.org/10.2147/DMSO.S275898 
4. Said, S., & Hernandez, G. T. (2014). The link between chronic kidney disease and cardiovascular disease. Journal of Nephropathology, 3(3), 99–104. https://doi.org/10.12860/jnp.2014.19 
5. Heart disease & kidney disease—Niddk. National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved June 25, 2026, from https://www.niddk.nih.gov/health-information/kidney-disease/heart-disease  
6. Choo, Y. N., Ravi, R. N., & Subramaniyan, V. (2026). Insulin resistance induced by obesity: Mechanisms, metabolic implications and therapeutic approaches. Molecular Biology Reports, 53(1), 357. https://doi.org/10.1007/s11033-026-11509-3 
7. Jha, R., Lopez-Trevino, S., Kankanamalage, H. R., & Jha, J. C. (2024). Diabetes and renal complications: An overview on pathophysiology, biomarkers and therapeutic interventions. Biomedicines, 12(5), 1098. https://doi.org/10.3390/biomedicines12051098 
8. Hall, M. E., do Carmo, J. M., da Silva, A. A., Juncos, L. A., Wang, Z., & Hall, J. E. (2014). Obesity, hypertension, and chronic kidney disease. International Journal of Nephrology and Renovascular Disease, 7, 75–88. https://doi.org/10.2147/IJNRD.S39739 
9. Heart and kidney disease: Connection, causes, symptoms, and treatment options | national kidney foundation. Retrieved June 25, 2026, from https://www.kidney.org/kidney-topics/heart-and-kidney-connection 
10. CDC. (2025, August 13). Chronic kidney disease, diabetes, and heart disease. Chronic Kidney Disease. https://www.cdc.gov/kidney-disease/risk-factors/link-between-diabetes-and-heart-disease.html 
11. Wang, Z., & Nakayama, T. (2010). Inflammation, a link between obesity and cardiovascular disease. Mediators of Inflammation, 2010, 535918. https://doi.org/10.1155/2010/535918 
12. Health threats from high blood pressure. Www.Heart.Org. Retrieved June 25, 2026, from https://www.heart.org/en/health-topics/high-blood-pressure/health-threats-from-high-blood-pressure  
13. Pappan, N., Awosika, A. O., & Rehman, A. (2026). Dyslipidemia. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK560891/ 
14. Chronic kidney disease (Ckd)—Symptoms, causes, treatment | National Kidney Foundation. (Retrieved June 25, 2026, from https://www.kidney.org/kidney-topics/chronic-kidney-disease-ckd 
15. Health risks of overweight & obesity. National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved June 25, 2026, from https://www.niddk.nih.gov/health-information/weight-management/adult-overweight-obesity/health-risks 
16. Xing, Y., Yang, X., & Zhao, Q. (n.d.). The association between family history of hypertension and diabetic kidney disease in patients with diabetes: A cross-sectional study. Frontiers in Endocrinology, 17, 1774744. https://doi.org/10.3389/fendo.2026.1774744 
17. Zhang, J., Huang, H., Lin, Z., Dong, J., Zhang, X., Gao, J., Liu, Y., Li, C., & Cui, Z. (2025). Associations between cardiovascular-kidney-metabolic syndrome and disability in activities of daily living: A nationwide longitudinal study among the middle-aged and older adults in China. Frontiers in Public Health, 12, 1480576. https://doi.org/10.3389/fpubh.2024.1480576 
18. Godoy-Matos, A. F., Valério, C. M., Júnior, W. S. S., de Araujo-Neto, J. M., Sposito, A. C., & Suassuna, J. H. R. (2025). CARDIAL-MS (Cardio-renal-diabetes-liver-metabolic syndrome): A new proposition for an integrated multisystem metabolic disease. Diabetology & Metabolic Syndrome, 17, 218. https://doi.org/10.1186/s13098-025-01796-4 
19. Alhindal, M., Janahi, J., D’Angelo, E. C., Lisignoli, V., Palmieri, R., Cutrì, A., Butera, G., Gatzoulis, M. A., & Montanaro, C. (2025). Impact of smoking on cardiovascular health: Mechanisms, epidemiology and specific concerns regarding congenital heart disease. International Journal of Cardiology Congenital Heart Disease, 20, 100581. https://doi.org/10.1016/j.ijcchd.2025.100581 
20. Jean-Louis, G., Zizi, F., Clark, L. T., Brown, C. D., & McFarlane, S. I. (2008). Obstructive sleep apnea and cardiovascular disease: Role of the metabolic syndrome and its components. Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine, 4(3), 261–272. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546461/ 
21.  Lassen, M. C. H., Ostrominski, J. W., Claggett, B. L., Ndumele, C. E., Biering-Sørensen, T., Matsushita, K., Selvin, E., Coresh, J., Shah, A., Solomon, S. D., & Vaduganathan, M. (2026). Cardiovascular–kidney–metabolic syndrome stages, echocardiographic characteristics, and heart failure risk: The atherosclerosis risk in communities study. Circulation, 153(17), 1268–1280. https://doi.org/10.1161/CIRCULATIONAHA.125.077894 

Diabetic nephropathy is one of the most significant long-term complications of diabetes, yet it often develops without clear warning in its early stages. Persistently high blood sugar places ongoing stress on the small blood vessels within the kidneys, gradually affecting their ability to filter waste and maintain the body’s internal balance. This process unfolds slowly, and for many individuals, it begins long before any symptoms become apparent.

Because early kidney damage does not usually cause pain or noticeable changes, it is frequently detected only through routine screening instead of clinical symptoms. As the condition progresses, signs such as swelling, fatigue or changes in urination may start to appear, reflecting a decline in kidney function.

What is diabetic nephropathy and how does it affect the kidneys?

The kidneys play a vital role in keeping the body in balance. They filter waste products and excess fluid from the blood, regulate electrolytes and help control blood pressure. This work is carried out by millions of tiny filtering units called glomeruli, which act as fine sieves, allowing waste to pass into the urine while retaining essential proteins and cells in the bloodstream [1].

Diabetic nephropathy develops when persistently high blood sugar begins to affect these delicate structures [2]. Over time, elevated glucose levels damage the small blood vessels within the glomeruli, making them less efficient and more permeable than they should be. As a result, important proteins, particularly albumin, start to leak into the urine, a change that is often one of the earliest detectable signs of kidney involvement in diabetes [3]. A urine albumin check is essential in diabetes monitoring for this reason.

As this damage progresses, the kidneys gradually lose their ability to filter waste effectively. Waste products can begin to build up in the blood, and the body’s fluid balance may be disrupted. Without timely management, this can lead to a steady decline in kidney function, increasing the risk of chronic kidney disease and, in advanced cases, kidney failure.

How does high blood sugar damage the kidneys over time?

High blood sugar does not damage the kidneys all at once. The effect builds gradually, as sustained glucose levels begin to alter how the kidneys function at a microscopic level. Over time, this ongoing strain disrupts normal filtration and places pressure on the kidney’s delicate structures, leading to progressive changes that can affect overall kidney health [4].

• Damage to small blood vessels — Prolonged high glucose levels weaken and injure the tiny blood vessels in the kidneys, affecting their ability to function properly.
• Increased pressure within the kidneys — The kidneys are forced to work harder, creating internal pressure that accelerates structural damage over time.
• Protein leakage into urine (albuminuria) — The filtering system becomes less selective, allowing proteins such as albumin to pass into the urine, often an early warning sign.
• Gradual decline in kidney function — As damage accumulates, the kidneys become less effective at filtering waste, leading to a slow reduction in function.

What are the early signs of diabetic kidney disease?

Diabetic kidney disease often develops quietly, especially in the early stages. Changes tend to begin at a microscopic level, which means there may be no obvious symptoms initially. This is why routine screening plays an important role in identifying early signs before noticeable complications arise.

• Often no symptoms in the early stages — Kidney damage can be present without any visible or physical signs, until it becomes ‘end-stage’ (too late to reverse).
• Microalbuminuria — Small amounts of protein (albumin) appear in the urine, usually detected through laboratory testing rather than symptoms.
• Mild swelling in the hands or feet — Fluid retention may develop as kidney function begins to change [5].
• Subtle fatigue — A general sense of tiredness may occur as the body’s ability to filter waste becomes less efficient.

What are the stages of diabetic nephropathy?

Diabetic nephropathy progresses through several stages, with each stage reflecting increasing levels of kidney involvement and declining function. Doctor’s will classify this differently and it will be based on EGFR (kidney blood test) as well as protein leakage (Using something called the KDIGO guidelines) but the unofficial stages below serve as a way to understand worsening kidney function and what happens. 

• Early stage (microalbuminuria) — At this stage, small amounts of albumin begin to leak into the urine, usually detected only through laboratory testing [6]. There are typically no symptoms, and kidney function remains largely preserved. This stage is clinically important because timely intervention can help slow or even halt further progression.
• Moderate stage (macroalbuminuria) — Protein leakage becomes more pronounced, indicating more established damage to the kidney’s filtering system [7]. Some individuals may begin to develop mild swelling or changes in blood pressure. Without appropriate management, kidney function may start to decline more noticeably during this phase.
• Advanced stage (chronic kidney disease) — The kidneys lose a significant portion of their filtering capacity [8]. Waste products and excess fluid begin to accumulate in the body, which may lead to symptoms such as fatigue, swelling, and reduced appetite. Medical management becomes more intensive at this stage to preserve remaining kidney function.
• End-stage kidney disease — Kidney function falls to a level where the kidneys can no longer adequately support the body’s needs. At this point, renal replacement therapy, such as dialysis or kidney transplantation, is required to maintain life.

Why is diabetic nephropathy often diagnosed late?

Diabetic nephropathy is often diagnosed at a later stage because its early course does not usually produce noticeable symptoms. The initial changes in kidney function develop gradually and remain clinically silent, which means there is little to prompt concern or medical evaluation based on how a person feels.

Another contributing factor is the absence of routine screening. Early indicators, such as small amounts of protein in the urine, can only be detected through specific tests. Without regular monitoring, these changes may go unnoticed for years, particularly in individuals who do not undergo consistent follow-up for diabetes.

By the time symptoms begin to appear, the condition has often progressed. Signs such as swelling, fatigue or changes in urination tend to reflect more advanced involvement, when kidney function has already been affected. 

When should you see an endocrinologist in Singapore?

It is important to seek specialist care when there are concerns about diabetes control or possible kidney involvement. An endocrinologist can carry out a detailed assessment, review your current treatment and monitor for early complications that may not yet be clinically obvious.

Persistent difficulty in controlling blood sugar levels, even with medication, is one of the most common reasons for referral. Abnormal findings on urine or blood tests, such as protein in the urine or a reduced eGFR, also require further evaluation. In addition, symptoms like swelling or unexplained fatigue may reflect changes in kidney function. Individuals with long-standing diabetes benefit from regular specialist review, as the risk of complications increases over time.

How is diabetic nephropathy diagnosed?

Diabetic nephropathy is usually identified through a combination of laboratory tests and clinical assessment, often before symptoms become apparent. These tests help detect early changes in kidney function and monitor progression over time.

• Urine albumin-to-creatinine ratio (ACR) — This test measures the amount of albumin in the urine relative to creatinine, providing a reliable indicator of abnormal protein leakage [9]. It is commonly used for routine screening, as even small increases can signal early kidney involvement before any symptoms develop.
• Blood tests (creatinine, eGFR) — Blood creatinine levels are used to calculate the estimated glomerular filtration rate (eGFR), which reflects how efficiently the kidneys are filtering waste [10]. A declining eGFR indicates reduced kidney function and helps determine the stage and progression of the condition.
• Blood pressure monitoring — Blood pressure is closely linked to kidney health, and elevated levels can both worsen kidney damage and result from it. Regular monitoring helps guide treatment decisions and is an essential part of managing diabetic nephropathy.

Can diabetic nephropathy be reversed or slowed down?

Diabetic nephropathy is not usually reversible once structural damage to the kidneys has developed. However, the course of the condition is not fixed, and progression/deterioration can often be slowed with timely and consistent management. Identifying changes at an early stage is particularly important, as intervention at this point can help preserve kidney function and delay further deterioration.

Strict blood sugar control remains central to this approach, as persistently elevated glucose levels continue to drive kidney damage. Alongside this, regular monitoring and appropriate medical care allow for adjustments in treatment based on how the condition is evolving. With a structured and proactive approach, many individuals are able to maintain stable kidney function for extended periods and reduce the likelihood of progression to advanced stages.

What treatments help protect kidney function?

Protecting kidney function in diabetic nephropathy requires a combination of medical treatment and ongoing disease management. The aim is to reduce stress on the kidneys, control contributing factors and slow further decline.

• Blood sugar management — Maintaining stable glucose levels helps reduce ongoing damage to the kidneys and is a key component of long-term control.
• Blood pressure control — Keeping blood pressure within target range reduces strain on the kidneys and lowers the risk of progression.
• Cholesterol management — Controlling cholesterol levels supports overall vascular health and reduces additional risk to the kidneys.
• Medications (ACE inhibitors, ARBs, SGLT2 inhibitors, Nonsteroidal Mineralocorticoid Antagonists, GLP-1 Agonists) — Medications now play a major role in protecting kidney function in people with diabetic nephropathy. Alongside blood sugar and blood pressure control, several newer medication groups have been shown to slow kidney damage, reduce protein leakage in the urine and lower the risk of progression to kidney failure [11]. In many patients, a combination of medications may be used as part of long-term kidney protection and cardiovascular risk reduction.
• ACE Inhibitors and ARBs — ACE inhibitors and angiotensin receptor blockers (ARBs) are commonly used to control blood pressure and reduce pressure within the kidneys [12]. They help lower protein leakage in the urine and slow the progression of diabetic kidney disease. These medications are often recommended even in the earlier stages of diabetic nephropathy when protein in the urine is detected [13].
• SGLT2 Inhibitors — SGLT2 inhibitors have become an important part of diabetic kidney disease management due to their significant kidney-protective benefits [14]. These medications help reduce excess glucose reabsorption in the kidneys and lower pressure within the filtering units of the kidneys. Studies have shown that SGLT2 inhibitors can slow decline in kidney function, reduce the risk of kidney failure and delay the need for dialysis in suitable patients [15]. This medication is fast becoming first-line especially in the context of kidney disease and can even improve kidney disease in patients without diabetes. 
• GLP-1 Receptor Agonists — GLP-1 receptor agonists help improve blood sugar control and may also provide cardiovascular and kidney benefits. In patients with type 2 diabetes and diabetic nephropathy, these medications help reduce progression of kidney disease while supporting weight management and metabolic health [16].
• Non-Steroidal Mineralocorticoid Receptor Antagonists (Finerenone) — Non-steroidal mineralocorticoid receptor antagonists such as finerenone may help reduce inflammation and scarring within the kidneys [17]. They are used in selected patients with diabetic kidney disease to further reduce the risk of kidney function decline and cardiovascular complications, particularly when kidney damage continues despite standard treatment.

What lifestyle changes can help protect your kidneys?

Lifestyle measures play an important role in supporting kidney health alongside medical treatment. Consistent, well-managed habits can reduce the overall burden on the kidneys and help stabilise blood sugar and blood pressure over time.

• Diet (reduced salt, balanced nutrition) — Limiting salt intake helps control blood pressure, which is closely linked to kidney health. A balanced diet that supports stable blood sugar levels can reduce ongoing stress on the kidneys and improve overall metabolic control.
• Regular exercise — Physical activity improves insulin sensitivity and helps maintain better glucose control. It also supports cardiovascular health, which is important because the kidneys rely on healthy blood vessels to function effectively.
• Weight management — Maintaining a healthy weight reduces the metabolic demand on the body and lowers the risk of worsening insulin resistance. This, in turn, helps reduce the progression of kidney-related complications.
• Avoiding smoking — Smoking damages blood vessels and can accelerate the decline in kidney function. Avoiding tobacco use helps preserve circulation and slows the progression of kidney disease.

What happens If diabetic nephropathy is left untreated?

Without appropriate management, diabetic nephropathy tends to progress over time, leading to a gradual but continuous decline in kidney function. The damage to the kidney’s filtering system does not stabilise on its own, and ongoing exposure to high blood sugar and associated factors continues to worsen the condition.

As kidney function declines, the body becomes less effective at removing waste products and excess fluid. This can result in the development of chronic kidney disease, where waste begins to accumulate in the bloodstream and affects overall health. Individuals may start to experience symptoms such as fatigue, swelling and reduced appetite as the condition advances.

In the later stages, kidney function may fall to a level where the kidneys can no longer support the body’s needs. At this point, renal replacement therapy becomes necessary. This may involve dialysis to filter the blood or, in suitable cases, a kidney transplant to restore function.

Summary 

Diabetic nephropathy is a progressive complication of diabetes that develops when persistently high blood sugar begins to affect the kidneys over time. The condition often starts without noticeable symptoms, which makes early detection through routine screening especially important. 

As the disease progresses, subtle changes such as protein in the urine may appear first, followed by a gradual decline in kidney function. If not identified and managed early, this can lead to chronic kidney disease and, in advanced cases, the need for dialysis or transplantation.

A clear understanding of how diabetic nephropathy develops highlights the importance of consistent management. Regular monitoring, good blood sugar control, appropriate medications and supportive lifestyle measures all play a role in slowing progression and protecting kidney function. With timely intervention, many individuals can maintain stable kidney health and reduce the risk of serious complications.

If you have diabetes or concerns about your kidney health, schedule a consultation with The Metabolic Clinic for a personalised assessment and early management plan. With appropriate lifestyle and medication changes, kidney deterioration can be halted.

References 

1. Your kidneys & how they work—Niddk. National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved May 8, 2026, from https://www.niddk.nih.gov/health-information/kidney-disease/kidneys-how-they-work 
2. Samsu, N. (2021). Diabetic nephropathy: Challenges in pathogenesis, diagnosis, and treatment. BioMed Research International, 2021, 1497449. https://doi.org/10.1155/2021/1497449 
3. Dabla, P. K. (2010). Renal function in diabetic nephropathy. World Journal of Diabetes, 1(2), 48–56. https://doi.org/10.4239/wjd.v1.i2.48 
4. McGrath, K., & Edi, R. (2019). Diabetic kidney disease: Diagnosis, treatment, and prevention. American Family Physician, 99(12), 751–759. 
5. What is diabetes-related nephropathy? Cleveland Clinic. Retrieved May 8, 2026, from https://my.clevelandclinic.org/health/diseases/24183-diabetic-nephropathy 
6. Zelmanovitz, T., Gerchman, F., Balthazar, A. P., Thomazelli, F. C., Matos, J. D., & Canani, L. H. (2009). Diabetic nephropathy. Diabetology and Metabolic Syndrome, 1, 10. https://doi.org/10.1186/1758-5996-1-10 
7. Chida, S., Fujita, Y., Ogawa, A., Hayashi, A., Ichikawa, R., Kamata, Y., Takeuchi, A., Takano, K., & Shichiri, M. (2016). Levels of albuminuria and risk of developing macroalbuminuria in type 2 diabetes: Historical cohort study. Scientific Reports, 6, 26380. https://doi.org/10.1038/srep26380 
8. Selby, N. M., & Taal, M. W. (2020). An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes, Obesity & Metabolism, 22 Suppl 1, 3–15. https://doi.org/10.1111/dom.14007 
9. Huan, L., Yuezhong, L., Chao, W., & HaiTao, T. (2016). The urine albumin-to-creatinine ratio is a reliable indicator for evaluating complications of chronic kidney disease and progression in IgA nephropathy in China. Clinics, 71(5), 243–250. https://doi.org/10.6061/clinics/2016(05)01 
10. Estimated gfr (Egfr) test: Kidney function levels, stages, and what to do next | national kidney foundation. Retrieved May 8, 2026, from https://www.kidney.org/kidney-topics/estimated-glomerular-filtration-rate-egfr 
11. Davis, K. N., Hines, A. E., Schaefer, M. C., & Naseman, K. W. (2022). Protecting the kidneys: Update on therapies to treat diabetic nephropathy. Clinical Diabetes : A Publication of the American Diabetes Association, 40(3), 305–311. https://doi.org/10.2337/cd21-0090 
12. Avula, A., Johal, L. K., Ali, F., Amir, S., Yadav, S., Murtuza, M., Zia, U., Janjua, F. F., Raza, A., Lal, K., Abid, M., & Khan, R. (n.d.). Ace inhibitors and arbs in chronic kidney disease: A systematic review of randomized controlled trials on albuminuria reduction, egfr decline, and safety. Cureus, 17(10), e93707. https://doi.org/10.7759/cureus.93707 
13. Vivian, E., & Mannebach, C. (2013). Therapeutic approaches to slowing the progression of diabetic nephropathy – is less best? Drugs in Context, 2013, 212249. https://doi.org/10.7573/dic.212249 
14. Padda, I. S., Mahtani, A. U., & Parmar, M. (2026). Sodium-glucose transport 2 (Sglt2) inhibitors. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK576405/ 
15. Yau, K., Dharia, A., Alrowiyti, I., & Cherney, D. Z. I. (2022). Prescribing sglt2 inhibitors in patients with ckd: Expanding indications and practical considerations. Kidney International Reports, 7(7), 1463–1476. https://doi.org/10.1016/j.ekir.2022.04.094 
16. Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. (2022). GLP-1 receptor agonists in diabetic kidney disease: Current evidence and future directions. Kidney Research and Clinical Practice, 41(2), 136–149. https://doi.org/10.23876/j.krcp.22.001 
17. Kolkhof, P., Lawatscheck, R., Filippatos, G., & Bakris, G. L. (2022). Nonsteroidal mineralocorticoid receptor antagonism by finerenone—Translational aspects and clinical perspectives across multiple organ systems. International Journal of Molecular Sciences, 23(16), 9243. https://doi.org/10.3390/ijms23169243
    

You've been managing your diabetes. You're checking your sugar levels, watching what you eat, taking your medication. What's easy to miss is that throughout all of this, something else may be quietly happening with your heart.

Diabetes doesn't just affect blood sugar. Over time, persistently elevated glucose damages the blood vessels that supply the heart, making them narrower, stiffer and more prone to blockage. This process often develops without symptoms. There may be no chest pain, no warning sign that suggests our cardiovascular system is under strain.

The risk compounds further because diabetes rarely travels alone. High blood pressure, altered cholesterol levels, and low-grade inflammation tend to accompany it, each adding to the burden on the heart. Together, they significantly raise the risk of heart disease, often appearing earlier, and progressing more quickly, than it would in someone without diabetes.

Understanding this connection is the first step to doing something about it.

The link between diabetes and our body

Diabetes is a long-term condition in which the level of glucose (sugar) in the blood remains higher than normal [1]. This happens because the body due to a reduced production of insulin +/- an inability to use insulin appropriately. Insulin is the hormone that helps move glucose from the bloodstream into the cells, where it is used for energy. When this process does not work effectively, glucose builds up in the blood instead of being used by the body.

There are two main types of diabetes:

• Type 1 diabetes — the body produces little or no insulin because the immune system attacks the insulin-producing cells in the pancreas.
  
• Type 2 diabetes — the body still produces insulin, but it does not respond to it properly (insulin resistance) and, there is not enough insulin to keep blood sugar levels within a normal range.

Over time, consistently raised blood sugar begins to affect how the body functions. Excess glucose in the bloodstream damages the lining of blood vessels, which makes them narrower and less flexible [2]. This affects circulation and reduces the delivery of oxygen and nutrients to vital organs.

The impact is not limited to one part of the body. Large blood vessels that supply the heart and brain can become affected, increasing the risk of heart disease and stroke [3]. At the same time, smaller vessels that support the eyes, kidneys and nerves can also be damaged, leading to complications such as vision problems, kidney disease and nerve damage [4].

These changes develop gradually and may not cause noticeable symptoms in the early stages. This is why diabetes is often described as a condition that works silently over time. 

Why does diabetes increase risk of heart disease?

Diabetes affects the heart gradually, often without obvious symptoms in the early stages. The increased risk comes from a combination of changes happening within the blood vessels and the body as a whole.

• Damage to blood vessels — Persistently high blood sugar damages the inner lining of the arteries [5]. Over time, the vessels become narrower and less flexible, making it easier for fatty deposits to build up and restrict blood flow to the heart.

• Ongoing inflammation — Diabetes is linked to low-grade inflammation in the body [6]. This weakens the blood vessels and makes them more prone to injury and plaque formation.

• Oxidative stress — High glucose levels increase the production of harmful molecules (free radicals). These damage the vessel walls further and speed up the process of hardening and narrowing of the arteries [7].

• Combined risk factors — Diabetes often occurs alongside other conditions such as high blood pressure and abnormal cholesterol levels [8]. Together, these places added strain on the heart and circulation.

Because of these overlapping effects, people with diabetes are more likely to develop:

• Coronary artery disease
• Heart attacks
• Heart failure

These conditions can also appear earlier and progress more quickly, which is why managing diabetes involves more than controlling blood sugar. 

How does high blood sugar damage the vessels?

High blood sugar does not just stay in the bloodstream; it begins to affect the structure and function of the blood vessels and the heart over time. These changes develop gradually, but they play a central role in increasing cardiovascular risk.

• Effects on the arteries (atherosclerosis) — Excess glucose damages the inner lining of the arteries, making them more prone to the build-up of fatty deposits. Over time, these deposits form plaques that narrow and harden the arteries, a process known as atherosclerosis [9]. This reduces the space through which blood can flow and increases the risk of blockages.

• Reduced circulation and oxygen supply — As the arteries narrow, blood flow becomes less efficient. The heart and other organs may not receive enough oxygen-rich blood, especially during physical activity or stress [10]. This reduced supply can lead to chest discomfort, fatigue or more serious complications if the blood flow is significantly restricted.

• Changes in heart muscle function — High blood sugar can also affect the heart muscle directly. It may lead to stiffness of the heart walls, making it harder for the heart to relax and fill properly. Over time, the heart may become less efficient at pumping blood, which can contribute to conditions such as heart failure [11]. Heart failure is one of the first complications of diabetes over time.

Early warning signs to look out for 

Heart problems do not always present clearly in people with diabetes. Some symptoms are typical, while others can be subtle or easily overlooked.

Typical symptoms 

• Chest discomfort or tightness
• Shortness of breath
• Fatigue with minimal activity
• Pain spreading to the left arm, neck or jaw

Silent or less obvious symptoms

Diabetes can affect nerve function, which may reduce the sensation of pain. This means some people may not experience the classic warning signs of heart problems. Instead, they may notice:

• Unexplained tiredness
• Mild breathlessness
• Dizziness or light-headedness
• A general sense of discomfort rather than clear pain

When to seek medical attention

Any new, persistent or worsening symptoms should not be ignored. Urgent medical care is needed if there is chest discomfort, sudden breathlessness, or symptoms that come on quickly. Regular check-ups are also important, even in the absence of symptoms, as some heart conditions in diabetes can develop quietly over time.

The silent heart disease 

Diabetes can lead to what is known as silent heart disease, where reduced blood flow to the heart occurs without the typical warning signs. This condition, often referred to as silent ischaemia, means that the heart may not be receiving enough oxygen, yet symptoms such as chest pain may be absent or very mild [16]. As a result, serious heart problems can develop without being recognised early.

A major reason for this is diabetic neuropathy, a form of nerve damage caused by prolonged high blood sugar [17]. When the nerves responsible for transmitting pain signals are affected, the body’s ability to detect discomfort is reduced. This can make symptoms less noticeable or entirely absent, even during significant cardiac events. Because of this, regular screening and routine medical assessments are essential for detecting heart issues early, as relying on symptoms alone may not provide a clear or timely indication of a problem.

Who is at higher risk of heart disease if they have diabetes?

The risk of heart disease in diabetes does not develop in the same way for everyone. Certain factors can increase how strongly diabetes affects the heart, especially when they are present over a long period or occur together.

• Longer duration of diabetes — The longer a person lives with diabetes, the more time high blood sugar has to damage the blood vessels. This gradual, cumulative effect increases the likelihood of narrowing arteries and reduced blood flow to the heart.

• Lifestyle habits — An unhealthy diet, lack of physical activity and smoking can accelerate vascular damage. These habits worsen blood sugar control and contribute to high blood pressure and cholesterol changes, all of which increase heart risk.

• Co-existing conditions — Conditions such as obesity and hypertension place additional strain on the cardiovascular system. When combined with diabetes, they create a higher overall burden on the heart and blood vessels.

• Age and family history — Older individuals naturally have a higher risk of heart disease due to age-related changes in the blood vessels. A family history of heart conditions can further increase susceptibility, even with good diabetes control.

Protecting your heart and managing diabetes

Managing diabetes effectively involves more than controlling blood sugar alone. A combination of daily habits and regular monitoring plays a key role in reducing strain on the heart and maintaining overall cardiovascular health.

• Blood sugar control — Keeping glucose levels within recommended targets helps prevent ongoing damage to blood vessels. Stable levels reduce the risk of long-term complications affecting the heart.

• Heart-healthy diet — A balanced diet supports both blood sugar and cholesterol control. This typically includes whole grains, vegetables, fruits, lean proteins such as fish or chicken and healthy fats like nuts, seeds and olive oil, while limiting processed foods and saturated fats.

• Regular physical activity — Consistent exercise, such as brisk walking, cycling or swimming, helps improve circulation and strengthens the heart. It also supports better blood sugar control and weight management.

• Weight management — Maintaining a healthy weight improves how the body uses insulin and reduces pressure on the heart. Even modest weight loss can lead to noticeable improvements in cardiovascular risk factors.

• Routine monitoring — Regular blood sugar monitoring, cholesterol checks and blood pressure measurements help identify any changes early. This allows timely adjustments to treatment and better long-term control of both diabetes and heart health.

• Use of Medication that reduces cardiovascular risk beyond its effect on blood sugar- Use of SGLT-2 class medications as well as GLP-1 class medications can reduce risk of heart attack and stroke as well as heart failure. And they work beyond their effects on blood sugar with effects that help the heart. 

Can heart damage from diabetes be reversed or managed?

Some of the effects of diabetes on the heart and blood vessels can improve with good control, especially when changes are made early. Better blood sugar management, along with control of blood pressure and cholesterol, can help stabilise existing damage and reduce further progression. In certain cases, improved lifestyle habits and appropriate treatment can enhance circulation and support heart function.

However, not all damage can be fully reversed. Advanced plaque build-up in the arteries or long-standing changes in the heart muscle can also be improved with medical guidance through optimisation of medication. The long-term outlook can still be positive when diabetes is well-managed. With consistent care, regular monitoring and appropriate medical support, many people are able to reduce complications, maintain quality of life and protect their heart health over time.

When should you see a doctor?

Knowing when to seek medical advice is an important part of managing both diabetes and heart health. Some symptoms require immediate attention, while others may develop gradually and still need timely evaluation.

• Red flag symptoms — Chest discomfort, tightness or pressure should always be taken seriously, especially if it spreads to the arm, neck or jaw. Sudden breathlessness, dizziness, unusual sweating or a feeling of faintness may also signal a heart problem and should not be ignored. Emergency services need to be contacted.

• Routine vs urgent consultation — Mild or ongoing symptoms such as fatigue, reduced exercise tolerance or intermittent breathlessness should be discussed during a routine medical review. However, symptoms that are sudden, severe or worsening, particularly chest pain or shortness of breath require urgent medical attention.

• Importance of early intervention — Heart conditions linked to diabetes can develop quietly, sometimes without clear warning signs. Early medical evaluation allows problems to be identified and managed before they progress. Regular check-ups, even in the absence of symptoms, play a key role in protecting long-term heart health.

Final thoughts

Diabetes affects more than blood sugar. Over time, it places real strain on the heart and blood vessels, often without obvious warning signs, which is why consistent management matters as much as it does.

The good news is that many of these risks are modifiable and recently there have been advances in medicine and  knowledge to prevent or improve cardiovascular risk. Keeping blood sugar stable, managing blood pressure and cholesterol, staying active and maintaining regular follow-up with your doctor can all make a meaningful difference to your long-term heart health.

If you are living with diabetes or have concerns about your cardiovascular health, schedule a consultation with The Metabolic Clinic for a personalised assessment, medication optimisation and guidance on managing your risk effectively.

References 

1. Diabetes. Retrieved April 17, 2026, from https://www.who.int/news-room/fact-sheets/detail/diabetes 
2. Yachmaneni, A., Jajoo, S., Mahakalkar, C., Kshirsagar, S., & Dhole, S. (n.d.). A comprehensive review of the vascular consequences of diabetes in the lower extremities: Current approaches to management and evaluation of clinical outcomes. Cureus, 15(10), e47525. https://doi.org/10.7759/cureus.47525 
3. Diabetes, heart disease, & stroke—Niddk. National Institute of Diabetes and Digestive and Kidney Diseases. Retrieved April 17, 2026, from https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/heart-disease-stroke  
4. Kulkarni, A., Thool, A. R., & Daigavane, S. Understanding the clinical relationship between diabetic retinopathy, nephropathy, and neuropathy: A comprehensive review. Cureus, 16(3), e56674. https://doi.org/10.7759/cureus.56674 
5. Liu, R., Li, L., Shao, C., Cai, H., & Wang, Z. (2022). The impact of diabetes on vascular disease: Progress from the perspective of epidemics and treatments. Journal of Diabetes Research, 2022, 1531289. https://doi.org/10.1155/2022/1531289 
6. Zhao, L., Hu, H., Zhang, L., Liu, Z., Huang, Y., Liu, Q., Jin, L., Zhu, M., & Zhang, L. (2024). Inflammation in diabetes complications: Molecular mechanisms and therapeutic interventions. MedComm, 5(4), e516. https://doi.org/10.1002/mco2.516 
7. Asmat, U., Abad, K., & Ismail, K. (2016). Diabetes mellitus and oxidative stress—A concise review. Saudi Pharmaceutical Journal : SPJ, 24(5), 547–553. https://doi.org/10.1016/j.jsps.2015.03.013 
8. Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018). Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms. The Canadian Journal of Cardiology, 34(5), 575–584. https://doi.org/10.1016/j.cjca.2017.12.005 
9. Poznyak, A., Grechko, A. V., Poggio, P., Myasoedova, V. A., Alfieri, V., & Orekhov, A. N. (2020). The diabetes mellitus–atherosclerosis connection: The role of lipid and glucose metabolism and chronic inflammation. International Journal of Molecular Sciences, 21(5), 1835. https://doi.org/10.3390/ijms21051835 
10. CDC. (2024, November 8). Diabetes and your heart. Diabetes. https://www.cdc.gov/diabetes/diabetes-complications/diabetes-and-your-heart.html 
11. Oktay, A. A., Paul, T. K., Koch, C. A., & Lavie, C. J. (2000). Diabetes, cardiomyopathy, and heart failure. In K. R. Feingold, R. A. Adler, S. F. Ahmed, B. Anawalt, M. R. Blackman, G. Chrousos, E. Corpas, W. W. de Herder, K. Dhatariya, K. Dungan, E. Hamilton, J. Hofland, S. Jan de Beur, S. Kalra, G. Kaltsas, N. Kapoor, M. Kim, C. Koch, P. Kopp, … D. P. Wilson (Eds.), Endotext. MDText.com, Inc. http://www.ncbi.nlm.nih.gov/books/NBK560257/ 
12.  Aronson, D., & Edelman, E. R. (2014). Coronary artery disease and diabetes mellitus. Cardiology Clinics, 32(3), 439–455. https://doi.org/10.1016/j.ccl.2014.04.001 
13.  Cui, J., Liu, Y., Li, Y., Xu, F., & Liu, Y. (2021). Type 2 diabetes and myocardial infarction: Recent clinical evidence and perspective. Frontiers in Cardiovascular Medicine, 8, 644189. https://doi.org/10.3389/fcvm.2021.644189 
14. Rosano, G. M., Vitale, C., & Seferovic, P. (2017). Heart failure in patients with diabetes mellitus. Cardiac Failure Review, 3(1), 52–55. https://doi.org/10.15420/cfr.2016:20:2 
15. Boudina, S., & Abel, E. D. (2010). Diabetic cardiomyopathy, causes and effects. Reviews in Endocrine & Metabolic Disorders, 11(1), 31–39. https://doi.org/10.1007/s11154-010-9131-7  
16. Abdul Manan, H., Chishti, H. R., & Hewlett, F. D. (n.d.). Prevalence and predictors of silent myocardial ischemia in diabetic patients. Cureus, 17(4), e82407. https://doi.org/10.7759/cureus.82407 
17. Yang, Y., Zhao, B., Wang, Y., Lan, H., Liu, X., Hu, Y., & Cao, P. (2025). Diabetic neuropathy: Cutting-edge research and future directions. Signal Transduction and Targeted Therapy, 10, 132. https://doi.org/10.1038/s41392-025-02175-1